These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2412024)

  • 21. Identification of nonserotonergic [3H]ketanserin binding sites associated with nerve terminals in rat brain and with platelets; relation with release of biogenic amine metabolites induced by ketanserin- and tetrabenazine-like drugs.
    Leysen JE; Eens A; Gommeren W; van Gompel P; Wynants J; Janssen PA
    J Pharmacol Exp Ther; 1988 Jan; 244(1):310-21. PubMed ID: 3336007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension.
    Zabludowski JR; Zoccali C; Isles CG; Murray GD; Robertson JI; Inglis GC; Fraser R; Ball SG
    Br J Clin Pharmacol; 1984 Mar; 17(3):309-16. PubMed ID: 6712863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of a selective 5-HT2 antagonist, ketanserin, on the pulmonary responses to Escherichia coli endotoxin.
    Ball HA; Parratt JR; Rodger IW
    Br J Pharmacol; 1983 Oct; 80(2):295-301. PubMed ID: 6360280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of ketanserin, methysergide and LY 53857 on sympathetic nerve activity.
    Ramage AG
    Eur J Pharmacol; 1985 Jul; 113(3):295-303. PubMed ID: 2931285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Neurohumoral and hemodynamic effects in combination therapy of enoximone and dopamine].
    Mitrovic V; Neuzner J; Opper H; Thormann J; Schlepper M
    Z Kardiol; 1994; 83 Suppl 2():37-48. PubMed ID: 8091823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Electrophysiologic profile of ibopamine in patients with congestive heart failure and ventricular tachycardia and relation to its effects on hemodynamics and plasma catecholamines.
    Van Veldhuisen DJ; Crijns HJ; Girbes AR; Tobé TJ; Wiesfeld AC; Lie KI
    Am J Cardiol; 1991 Nov; 68(11):1194-202. PubMed ID: 1683146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular effects in the rat of ketanserin, a novel 5-hydroxytryptamine receptor blocking agent.
    Persson B; Hedner T; Henning M
    J Pharm Pharmacol; 1982 Jul; 34(7):442-5. PubMed ID: 6126541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can peripheral serotonergic blockade explain the hypotensive effect of ketanserin?
    Vanhoutte PM
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S105-9. PubMed ID: 2412025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet hypersensitivity to serotonin after prolonged ketanserin intake?
    Arnout J; Van Russelt M; Deckmyn H; Vermylen J; Fiocchi R; Lijnen P; Amery A
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S20-2. PubMed ID: 2412049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ketanserin: a possible tool for studying the role of serotonin in hypertension.
    Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of ketanserin, a 5-HT2-receptor antagonist, on the blood flow response to temperature changes in the diabetic foot.
    Schneider SH; Tendler M; Apelian A; Jageneau AH; Khachadurian AK
    J Clin Pharmacol; 1985 Sep; 25(6):413-7. PubMed ID: 2932476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries.
    Bush LR; Campbell WB; Kern K; Tilton GD; Apprill P; Ashton J; Schmitz J; Buja LM; Willerson JT
    Circ Res; 1984 Nov; 55(5):642-52. PubMed ID: 6488486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of ketanserin on central haemodynamics and coronary circulation.
    Hood S; Birnie D; Nasser A; Hillis WS
    J Cardiovasc Pharmacol; 1998 Dec; 32(6):983-7. PubMed ID: 9869505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ketanserin, a serotonin antagonist. Administration in patients with acute respiratory failure.
    Vincent JL; Degaute JP; Domb M; Simon P; Berre J; Vandesteene A
    Chest; 1984 Apr; 85(4):510-3. PubMed ID: 6705581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure.
    Cavero PG; De Marco T; Kwasman M; Lau D; Liu M; Chatterjee K
    J Am Coll Cardiol; 1992 Dec; 20(7):1542-8. PubMed ID: 1452928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of ketanserin on phenylephrine-dependent changes in splanchnic hemodynamics and systemic blood pressure in healthy subjects.
    Gasic S; Eichler HG; Korn A
    J Cardiovasc Pharmacol; 1985; 7(2):219-23. PubMed ID: 2581071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympathoadrenal function in normal man.
    Zoccali C; Zabludowski JR; Isles CG; Murray GD; Inglis GC; Robertson JI; Fraser R; Ball SG
    Br J Clin Pharmacol; 1983 Sep; 16(3):305-11. PubMed ID: 6626423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine.
    McGoon MD; Vanhoutte PM
    J Clin Invest; 1984 Sep; 74(3):828-33. PubMed ID: 6470141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ketanserin (S2-receptor blocking agent), platelet activity and chronic alcoholism.
    Santini P; Ceccanti M; De Lorenzo A; Pisculli M; Di Giovanni MG; Cavaleri G; Attilia ML; Berbellini A
    Int J Clin Pharmacol Res; 1986; 6(1):73-6. PubMed ID: 2937746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological manipulation of cardiovascular responses to lower body negative pressure.
    Perko G; Schmidt JF; Warberg J; Secher NH
    Eur J Appl Physiol Occup Physiol; 1996; 73(5):459-64. PubMed ID: 8803507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.